Biotech News

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva (INVA)InnovivaCompany update

WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 11, 2026-- Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO ® (sulbactam/durlobactam for injection), ZEVTERA ® (ceftobiprole medocaril sodium

Related news

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

INVAInnoviva2026-10-19 12:00 EST

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

FULCFulcrum Therapeutics2026-08-17 11:00 EST

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

FULCFulcrum Therapeutics2026-06-01 20:05 EST

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

RHHBYRoche Holdings AG2026-10-16 05:00 EST

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

RHHBYRoche Holdings AG2026-11-16 06:00 EST

Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

Innoviva

Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...

Recent company news

Stock data

Close
18.41 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States